Lasmiditan, sold under the brand name Reyvow, is a medication used for the acute, active but short-term, treatment of migraine with or without aura in adults.
It is not useful for prevention.
It is taken by mouth.
Routes of administration-By mouth, intravenous
Common side effects include sleepiness, dizziness, tiredness, and numbness.
A first-in-class medication.
Lasmiditan is a serotonin receptor agonist that selectively binds to the 5-HT1F receptor subtype.
A number of triptans have been shown to act on this subtype as well.
Adverse effects:
There is a risk of driving impairment: advised not to drive or operate machinery for at least eight hours after taking lasmiditan.
The drug causes central nervous system (CNS) depression, including dizziness and sedation.
It should be used with caution if taken in combination with alcohol or other CNS depressants.
A statistically significantly greater percentage of subjects were free of their most bothersome symptom compared with placebo at two hours following the first dose.